NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

CaptainObvious, I believe with the current DCVax-L Phase 3 trial approval. Remember, as Dr. Liau said. you can not patent patient's cells, blood or tissue. You have to patent the process of making DCVax-L, and that is what NWBio has done.

DCVax-L is made from each patients own tumor cells, tissue and blood. Each patient's dendritic cells have to be matured and activated through a process to make each patients own DCVax-L vaccine. NWBio's patented processes allows them to use a choice of several different maturation and activation agents for the patient's dendritic cells.

One of the maturation and activation agents that NWBio's DCVax-L process patents allows them to use to make DCVax-L is poly-ICLC. When NWBio uses poly-ICLC to mature and activate the dendritic cells, it is still DCVax-L made from the patient's own dendritic cells. Using poly-ICLC does not change the essence of DCVax-L, it is still DCVax-L.

EDIT: This means when DCVax-L is approved by all regulatory authorities soon, the combination of DCVax-L + poly-ICLC (DCVax-L 2.0) will also be approved.